Company Description
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally.
It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions.
In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench.
Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data.
It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries.
Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 2008 |
| IPO Date | Dec 11, 2020 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 1,391 |
| CEO | William Feehery |
Contact Details
Address: 100 Overlook Center, Suite 101 Princeton, New Jersey 08540 United States | |
| Phone | 609 716 7900 |
| Website | certara.com |
Stock Details
| Ticker Symbol | CERT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 0001827090 |
| CUSIP Number | 15687V109 |
| ISIN Number | US15687V1098 |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| Dr. William F. Feehery Ph.D. | Chief Executive Officer and Director |
| Leif E. Pedersen | President and Chief Commercial Officer |
| John E. Gallagher III | SVice President, Principal Accounting Officer and Chief Financial Officer |
| Dr. Robert P. Aspbury Ph.D. | President of Certara Scientific Software |
| Dr. Patrick F. Smith Pharm.D. | President of Certara Drug Development Solutions |
| Max Kanevsky | Chief Technology Officer |
| Daniel Corcoran | Chief Counsel |
| Ron DiSantis | Senior Vice President of Corporate Development |
| Sheila Rocchio MBA | Chief Marketing Officer |
| Rona Anhalt | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 16, 2024 | 8-K | Current Report |
| Oct 7, 2024 | 144 | Filing |
| Oct 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 9, 2024 | 144 | Filing |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Jul 19, 2024 | 8-K | Current Report |